Skip navigation

Emerging Trends and Compliance Risks Associated with Anti-Bribery and Anti-Corruption, HCP Sponsorships and Patient Interactions

February 26-27, 2020
  • Kyoto, Japan

Rapidly evolving global regulations are deeply affecting business operations in Asia, especially as the pharmaceutical and medical device markets grow in this region. With the U.S., UK and local Asian regulatory bodies increasing their ABAC enforcements, multinational life sciences companies must be more vigilant than ever. Compliance professionals are tasked with building and maintaining effective compliance programs to meet these multi-jurisdictional requirements while still aligning with the needs of the business.

Informa Connect’s Pharmaceutical Compliance Congress (PCC) Asia is the only event for compliance teams, providing novel approaches and advanced strategies for this quickly transforming regulatory landscape.

Key Issues to be Explored:

  • Compliance as a dual function – business partner and role model
  • Anti-Corruption and Anti-Bribery
  • Third-Party Oversight
  • Transparency
  • HCP Sponsorships
  • Grants and Donations
  • Data Privacy
  • And more!

Featuring in-depth content and insights around the most
important compliance issues in Japan, China, South Korea,
Indonesia, Singapore, Thailand, Vietnam and Malaysia.

Questions to be Discussed in 2020:

  • How do you setup compliance training programs as an ongoing practice to increase compliance awareness throughout your organization?
  • How will the automation and digital solutions impact your compliance program
  • How can compliance support business intelligence through data analytics? And partner with business units to achieve organizational goals?
  • Are compliance and ethics initiatives part of your companies’ broader mission?

Previous Attendee Acclaim:

CBI always provides insightful speakers who share their worldly experience on important healthcare topics.

Senior Director, Compliance, GlaxoSmithKline

Pharmaceutical Compliance Congress Asia

Emerging Trends and Compliance Risks Associated with Anti-Bribery and Anti-Corruption, HCP Sponsorships and Patient Interactions

Rapidly evolving global regulations are deeply affecting business operations in Asia, especially as the pharmaceutical and medical device markets grow in this region. With the U.S., UK and local Asian regulatory bodies increasing their ABAC enforcements, multinational life sciences companies must be more vigilant than ever. Compliance professionals are tasked with building and maintaining effective compliance programs to meet these multi-jurisdictional requirements while still aligning with the needs of the business.

Informa Connect’s Pharmaceutical Compliance Congress (PCC) Asia is the only event for compliance teams, providing novel approaches and advanced strategies for this quickly transforming regulatory landscape.

Key Issues to be Explored:

  • Compliance as a dual function – business partner and role model
  • Anti-Corruption and Anti-Bribery
  • Third-Party Oversight
  • Transparency
  • HCP Sponsorships
  • Grants and Donations
  • Data Privacy
  • And more!

Featuring in-depth content and insights around the most
important compliance issues in Japan, China, South Korea,
Indonesia, Singapore, Thailand, Vietnam and Malaysia.

Questions to be Discussed in 2020:

  • How do you setup compliance training programs as an ongoing practice to increase compliance awareness throughout your organization?
  • How will the automation and digital solutions impact your compliance program
  • How can compliance support business intelligence through data analytics? And partner with business units to achieve organizational goals?
  • Are compliance and ethics initiatives part of your companies’ broader mission?

Previous Attendee Acclaim:

CBI always provides insightful speakers who share their worldly experience on important healthcare topics.

Senior Director, Compliance, GlaxoSmithKline